PSMA-dRT: Imaging Prior to Radiation for Intermediate-, High-Risk Prostate Cancer

Jérémie Calais, MD, PhD, of the University of California, Los Angeles, explains the purpose of the PSMA-dRT trial and why it closed early, as well as the utility of PSMA PET prior to definitive radiation therapy for unfavorable intermediate- or high-risk prostate cancer.

He ends with a note on plans to further assess PSMA PET in this setting, including for prostate cancer salvage radiotherapy management.

Data from the PSMA-dRT trial were presented at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium.